Welcome to Merz Therapeutics North America

At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients’ quality of life.

Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is headquartered in Frankfurt, Germany and is represented in more than 90 countries. Our Merz Therapeutics North America business is composed of affiliates in the U.S. and Canada and has regional headquarters in Raleigh, N.C. To visit the Merz Canada website and for more information on our Canada business, please click here.

Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that serve unmet patient and customer needs.

News

MERZ THERAPEUTICS TO PRESENT ROBUST DATA ON XEOMIN® (INCOBOTULINUMTOXINA) AT TOXINS 2022 CONFERENCE

RALEIGH, N.C. , July 27, 2022

Merz Therapeutics announced today the presentation of data from 10 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2022: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place in New Orleans, LA July 27-30.

MERZ THERAPEUTICS DONATES $100,000 TO SUPPORT CONSTRUCTION OF NEW REHABILITATION CENTER AT UNIVERSITY OF NORTH CAROLINA

Raleigh, N.C., August 17, 2021

Merz Therapeutics announced today its U.S. organization has made a $100,000 donation to the University of North Carolina (UNC) Health Foundation to assist in funding construction and capital expenses of UNC Health’s new Acute Inpatient Rehabilitation Center (the “AIR Center”), scheduled to open in Hillsborough, N.C. in February 2022.

XEOMIN® (INCOBOTULINUMTOXINA) SAFETY AND EFFICACY DATA FOR TREATMENT OF PEDIATRIC CHRONIC SIALORRHEA PUBLISHED IN NEUROLOGY

Raleigh, N.C., August 9, 2021

Merz Therapeutics announced today the online publication of the article “SIPEXI: Placebo-controlled clinical trial of incobotulinumtoxinA for sialorrhea in children” in Neurology, the premier peer-reviewed journal for clinical neurology research.

Contact Us

Title*
Name*
Phone*
Email*
City*
State*
Message*
If you would like to report a possible side effect or complaint for a therapeutic product in the United States, please contact 844-469-6379 (844-4MY-MERZ). For reports regarding therapeutic products in Canada, please click here.
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.

* mandatory fields

Please note that if you submit information to Merz all materials submitted by electronic or physical communication will be deemed non-confidential. Do not submit any information or other materials that you consider to be confidential or proprietary. While we have no intention to publicly disclose any details of your proposal, we may refer to select experts within or outside the Merz network for evaluation.